NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it is the first firm to meet draft guidelines being developed by the International Organization for Standardization to minimize the risk of human DNA contamination in forensics products.

The firm's Warrington, UK manufacturing site was confirmed to be in adherence to the draft standard by a forensic quality and validation expert, the firm said.

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.